What is Moderna's (mRNA) stock price?
What is Moderna's stock price today? One share of MRNA stock can currently be purchased for approximately $127.03.
How do I buy mRNA stocks?
Research the stock. Find the stock by name or ticker symbol – MRNA – and research it before deciding if it's a good investment for you. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price. Check in on your investment.
Where can I buy Moderna stock?
Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Moderna's stock price today? One share of MRNA stock can currently be purchased for approximately $165.09. How much money does Moderna make?
What percentage of Moderna shares are insiders?
Currently 9.491% of Moderna shares are held by insiders and 61.177% by institutions. How many people work for Moderna? Latest data suggests 1,300 work at Moderna.
Is Moderna a buy right now?
14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 1 sell rating, 8 h...
When is Moderna's next earnings date?
Moderna is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Moderna .
How were Moderna's earnings last quarter?
Moderna, Inc. (NASDAQ:MRNA) issued its earnings results on Wednesday, May, 4th. The company reported $8.58 earnings per share (EPS) for the quarter...
What price target have analysts set for MRNA?
14 Wall Street analysts have issued twelve-month target prices for Moderna's shares. Their forecasts range from $80.00 to $395.00. On average, they...
Who are Moderna's key executives?
Moderna's management team includes the following people: Dr. Noubar B. Afeyan Ph.D. , Co-Founder, Independent Non Exec. Chairman & Member of Tech...
What is Stéphane Bancel's approval rating as Moderna's CEO?
57 employees have rated Moderna CEO Stéphane Bancel on Glassdoor.com . Stéphane Bancel has an approval rating of 92% among Moderna's employees. Th...
Who are some of Moderna's key competitors?
Some companies that are related to Moderna include Amgen (AMGN) , Gilead Sciences (GILD) , BioNTech (BNTX) , Biogen (BIIB) , Seagen (SGEN) ,...
What other stocks do shareholders of Moderna own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA) , Tesla (TSLA...
When did Moderna IPO?
(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00...
Is Moderna stock a Buy, Sell or Hold?
Moderna stock has received a consensus rating of hold. The average rating score is and is based on 21 buy ratings, 27 hold ratings, and 8 sell rati...
What was the 52-week low for Moderna stock?
The low in the last 52 weeks of Moderna stock was 119.02. According to the current price, Moderna is 124.06% away from the 52-week low.
What was the 52-week high for Moderna stock?
The high in the last 52 weeks of Moderna stock was 497.00. According to the current price, Moderna is 29.71% away from the 52-week high.
What are analysts forecasts for Moderna stock?
The 56 analysts offering price forecasts for Moderna have a median target of 186.50, with a high estimate of 463.00 and a low estimate of 41.00. Th...
Is Moderna stock down?
Is Pfizer crushing Moderna?
Shares of Moderna Inc. were down 1.2% in premarket trading on Wednesday after the company said the U.S. has agreed to buy an additional 200 million doses of its COVID-19 vaccine. This agreement includes the option to purchase other COVID-19 vaccine candidates that Moderna is developing. This could include booster shots, Moderna executives said in a news release. In total, the U.S. has ordered 500 million doses of the company's mRNA vaccine. Moderna's stock has soared 92.9% this year, while the S
Does Moderna work in Japan?
3 Areas Where Pfizer Is Crushing Moderna. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been marching in lockstep for nearly a year. Pfizer won Emergency Use Authorization for its vaccine only about a week ahead of Moderna. It's fair to say both of these companies today are leading the coronavirus vaccine market.
Did the US buy Moderna?
Takeda Pharmaceutical Co said on Tuesday it agreed to supply an additional 50 million doses of Moderna In c's COVID -19 vaccine to Japan. Takeda CEO Christophe Weber had said in May that talks were underway to potentially double the Moderna shipments to help Japan speed up its inoculation efforts.
How much is Moderna worth in 2020?
The U.S. government has bought another 200 million doses of Moderna's COVID-19 vaccine, the drugmaker said on Wednesday, including an option to buy experimental shots that may be in development. Moderna is currently conducting clinical trials testing a third booster shot of its authorized vaccine as well as an experimental one to protect against coronavirus variants. The U.S. government last August signed a $1.53 billion deal with Moderna for 100 million vaccine doses, with an option to buy 400 million more.
What is Moderna based on?
If you had bought $1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $16.00.
How effective is Moderna?
Moderna, Inc. , a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.
What is Moderna's EBITDA?
On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.
What was the last closing price of Moderna?
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
Is Moderna a peer reviewed study?
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement. Its last close price was $338.40, which is 94.61% up on its pre-crash value of $18.23 and 1,789.45% up on the lowest point reached during the March crash when the shares fell as low as $17.91.
Is Moderna approved by the FDA?
Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.
Topline
Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. The vaccine has yet to be approved by the FDA, but the company has applied for emergency authorization and the first doses could be distributed this year, the Washington Post reported Nov. 30.
Key Facts
Battered by a steep broad-market selloff this week, Moderna shares fell for a sixth straight day Friday as experts questioned whether Covid-19 vaccine sales alone will help justify the firm’s meteoric valuation, intensifying a crash that’s wiped out more than 60% of the value in one of last year’s top stocks and turned it into this year’s worst performer..
Surprising Fact
Moderna stock fell 4.4% Friday to an eight-month low of $160, pushing shares down more than 20% over the past week amid growing research suggesting Moderna’s Covid-19 booster, while very effective against previous strains, has been less effective against the rapidly spreading omicron variant.
Tangent
Shares of Moderna have plunged 67% from an all-time closing high of $484 on August 9, wiping out about $133 billion from the firm’s market capitalization, which now stands at roughly $65 billion.
Key Background
Though it skyrocketed 143% to land the S&P 500’s third-best gain in 2021, Moderna stock has plummeted 35% this year—even worse than Netflix, which is down 32% after a steep 20% plunge Friday following a disappointing earnings report.
What To Watch For
Founded in 2010, Cambridge, Massachusetts-based Moderna spent nearly a decade developing the technology for its messenger RNA vaccines, which tell the body to produce part of a pathogen to trigger an immune response—unlike traditional vaccines that instead use a piece of the pathogen.
NASDAQ: MRNA
Moderna is expected to report fourth-quarter earnings by the end of February.
You'd be sitting pretty, to say the least
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Was the stock a buy before 2020?
Moderna ( MRNA -4.74% ) is one of the hottest biotechs on the market thanks to its rapid development of a functional coronavirus vaccine. Fueled by astronomically high predictions of its vaccine revenue, the stock continues to ascend higher and higher.
NASDAQ: MRNA
With an abundance of fanfare, Moderna went public in late 2018, and it was the largest biotech initial public offering (IPO) in history at the time. The company already had a reputation for a frothy valuation thanks to significant fundraising with the help of its venture capital partners.
Investing extremely early wasn't necessary to win big
Still, there were a few reasons to find the company appealing at the time, starting with its then-unproven mRNA technology platform.
Sometimes it's better not to worry about being too late
Let's assume that as a savvy biotech investor with a diversified portfolio, you found Moderna's pipeline to be especially attractive and made a speculative investment of $2,000 on Sep. 9, 2019, when Moderna's stock was at $16.71. Now, it's around $431, and it could rise even further over the next few months.
Premium Investing Services
To be clear, Moderna was still a speculative purchase in April of 2020. At that point, wise investors were hedging their bets by making small positions in a handful of different vaccine developers. Nonetheless, even conservative investors had a significant opportunity to get a huge return from this stock.
